• If you are wondering whether CME Group is starting to look attractively priced after recent volatility, this article breaks down what the current share price might be implying about value.
• The stock closed at US$242.26, with the share price declining 7.4% over the last week and 16.8% over the past month, while still showing gains of 53.9% over three years and 40.1% over five years.
• Recent price moves have come as investors reassess CME Group's role as a major exchange operator and derivatives platform in a period where trading volumes and risk appetite can shift quickly. Longer term performance figures help frame whether current weakness is just a pullback within a multi year climb or a sign that expectations are being reset.
• CME Group currently has a valuation score of 4 out of 6. This suggests some areas of potential undervaluation that will be unpacked using multiple methods, before circling back at the end to a broader way of thinking about what valuation really tells you.

Approach 1: CME Group Excess Returns Analysis

The Excess Returns model for CME Group looks at how much earnings exceed the company’s estimated cost of equity, then capitalizes those extra returns to estimate what the stock could be worth today.

On this view, CME Group is starting from a Book Value of $73.57 per share and a Stable EPS of $13.69 per share, based on weighted future Return on Equity estimates from 5 analysts. The Average Return on Equity is 16.63%, while the model assigns a Cost of Equity of $6.45 per share, implying an Excess Return of $7.24 per share.

The model also uses a Stable Book Value of $82.32 per share, sourced from weighted future Book Value estimates from 4 analysts. These inputs are used to project how much value CME Group can create above its equity cost and to discount those excess returns back into a single intrinsic value estimate.

That intrinsic value is $250.74 per share, compared with the recent share price of $242.26, implying CME Group stock is around 3.4% undervalued.

Result: ABOUT RIGHT

CME Group is fairly valued according to our Excess Returns, but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: CME Group Price vs Earnings

For a profitable company like CME Group, the P/E ratio is a useful snapshot of how much investors are paying for each dollar of earnings. It ties the stock price directly to current profitability, which many investors treat as a core anchor for value.

What counts as a “normal” P/E depends on what the market expects from a company’s future earnings and how risky those earnings appear. Higher expected growth or lower perceived risk often supports a higher P/E, while slower growth or higher risk tends to align with a lower multiple.

CME Group currently trades on a P/E of 20.68x. This sits below the broader Capital Markets industry average P/E of 40.52x and also below the peer group average of 24.86x. Simply Wall St’s Fair Ratio framework goes further by estimating what P/E might make sense for CME Group specifically, using factors such as earnings growth, profit margins, industry, market cap and company specific risks.

On this basis, CME Group’s Fair Ratio is 16.37x, which is lower than the current 20.68x P/E, so the stock price is above what this model suggests is justified.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your CME Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the story you believe about CME Group, connect it to a simple forecast for future revenue, earnings and margins, then translate that into your own fair value. You can compare this against the current share price on Simply Wall St's Community page, where these Narratives are available and updated automatically when fresh news or results arrive. They can differ widely. For example, one investor might build a Narrative that aligns with the highest analyst price target of US$353.00, while another might lean toward the more cautious US$230.00 view. Yet both are using the same framework to decide whether CME Group looks expensive or cheap relative to their personal fair value.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.